These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9440766)

  • 21. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
    Sawaki M; Tokudome N; Mizuno T; Nakayama T; Taira N; Bando H; Murakami S; Yamamoto Y; Kashiwaba M; Iwata H; Uemura Y; Ohashi Y
    Jpn J Clin Oncol; 2011 May; 41(5):709-12. PubMed ID: 21355003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
    Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
    J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of mitoxantrone in the treatment of breast cancer.
    Hainsworth JD
    Semin Oncol; 1995 Feb; 22(1 Suppl 1):17-20. PubMed ID: 7863347
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective.
    Daugherty CK
    J Clin Oncol; 1999 May; 17(5):1601-17. PubMed ID: 10334550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
    Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
    J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients' concerns about clinical trials in Japan.
    Aoki E
    Lancet; 1999 Mar; 353(9157):1019-20. PubMed ID: 10459946
    [No Abstract]   [Full Text] [Related]  

  • 27. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide for metastatic breast cancer.
    Atkins CD
    J Clin Oncol; 2001 Jul; 19(14):3441-2. PubMed ID: 11454896
    [No Abstract]   [Full Text] [Related]  

  • 28. [Chemotherapy of disseminated forms of breast cancer using platinum derivatives].
    Gorbunova VA; Trofimova NB; Manziuk LV
    Vopr Onkol; 1990; 36(4):455-7. PubMed ID: 2345995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal chemotherapy for women with breast cancer: the plot thickens.
    Pater JL; Pritchard KI
    J Clin Oncol; 2003 Mar; 21(6):963-4. PubMed ID: 12637457
    [No Abstract]   [Full Text] [Related]  

  • 30. Ethical considerations in randomized controlled clinical trials.
    Kodish E; Lantos JD; Siegler M
    Cancer; 1990 May; 65(10 Suppl):2400-4. PubMed ID: 2185875
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?
    Fumoleau P; Bonneterre J; Luporsi E
    J Clin Oncol; 2003 Mar; 21(6):1190-1; author reply 1191-2. PubMed ID: 12637489
    [No Abstract]   [Full Text] [Related]  

  • 32. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
    Sauter C
    Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
    [No Abstract]   [Full Text] [Related]  

  • 33. [Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].
    Cavalli F
    Schweiz Med Wochenschr; 1994 Oct; 124(43):1882-4. PubMed ID: 7973514
    [No Abstract]   [Full Text] [Related]  

  • 34. Equipoise and the ethics of randomization.
    Lilford RJ; Jackson J
    J R Soc Med; 1995 Oct; 88(10):552-9. PubMed ID: 8537943
    [No Abstract]   [Full Text] [Related]  

  • 35. The patient as partner: ethics in clinical oncology research.
    Veatch RM
    Johns Hopkins Med J; 1982 Oct; 151(4):155-61. PubMed ID: 7120718
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of metastatic breast cancer--economic and ethical considerations.
    Richter G
    Cancer Invest; 1997; 15(4):335-41. PubMed ID: 9246156
    [No Abstract]   [Full Text] [Related]  

  • 37. The standard of disclosure in human subject experimentation.
    Morin K
    J Leg Med; 1998 Jun; 19(2):157-221. PubMed ID: 9658739
    [No Abstract]   [Full Text] [Related]  

  • 38. Human experimentation. Protecting patient autonomy through informed consent.
    Tuthill KA
    J Leg Med; 1997 Jun; 18(2):221-50. PubMed ID: 9230568
    [No Abstract]   [Full Text] [Related]  

  • 39. Paclitaxel-based combination chemotherapy for breast cancer.
    Hortobagyi GN
    Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):29-37. PubMed ID: 9110340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):192-3. PubMed ID: 12202899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.